Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Mosapramine

From Wikipedia, the free encyclopedia
Antipsychotic medication
Pharmaceutical compound
Mosapramine
Clinical data
Trade namesCremin (クレミン,JP)
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral (tablets, oral solution)
ATC code
Legal status
Legal status
  • Rx-only (JP)
Identifiers
  • 1'-[3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl]spiro[1,5,6,7,8,8a-hexahydroimidazo[1,2-a]pyridine-3,4'-piperidine]-2-one
CAS Number
PubChemCID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC28H35ClN4O
Molar mass479.07 g·mol−1
3D model (JSmol)
  • C1CCN2C(C1)NC(=O)C23CCN(CC3)CCCN4C5=CC=CC=C5CCC6=C4C=C(C=C6)Cl
  • InChI=1S/C28H35ClN4O/c29-23-12-11-22-10-9-21-6-1-2-7-24(21)32(25(22)20-23)16-5-15-31-18-13-28(14-19-31)27(34)30-26-8-3-4-17-33(26)28/h1-2,6-7,11-12,20,26H,3-5,8-10,13-19H2,(H,30,34)
  • Key:PXUIZULXJVRBPC-UHFFFAOYSA-N
  (verify)

Mosapramine (Cremin) is anatypical antipsychotic used inJapan for the treatment ofschizophrenia.[1][2] It is a potentdopamine antagonist with high affinity to theD2,D3, andD4receptors,[3] and with moderate affinity for the5-HT2 receptors.[4]

See also

[edit]

References

[edit]
  1. ^Takahashi N, Terao T, Oga T, Okada M (1999). "Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia".Neuropsychobiology.39 (2):81–5.doi:10.1159/000026565.PMID 10072664.S2CID 6554048.
  2. ^Miyamoto S (2010)."Mosapramine". In Stolerman IP (ed.).Encyclopedia of Psychopharmacology. Berlin, Heidelberg: Springer. p. 76.doi:10.1007/978-3-540-68706-1_1839.ISBN 978-3-540-68706-1. Retrieved21 March 2022.
  3. ^Futamura T, Ohashi Y, Yano K, Takahashi Y, Haga K, Fukuda T (May 1996)."[The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors]".Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica.107 (5):247–53.doi:10.1254/fpj.107.247.PMID 8690306.
  4. ^Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Mori H, Shiba K, Yokogawa K (February 1995). "Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy".Neuropsychopharmacology.12 (1):57–64.doi:10.1016/0893-133X(94)00064-7.PMID 7766287.
Typical
Disputed
Atypical
Others
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(andprodrugs)
nAChRsTooltip Nicotinic acetylcholine receptors
Agonists
(andPAMsTooltip positive allosteric modulators)
Antagonists
(andNAMsTooltip negative allosteric modulators)
Precursors
(andprodrugs)
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
H1
Agonists
Antagonists
H2
Agonists
Antagonists
H3
Agonists
Antagonists
H4
Agonists
Antagonists
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Classes
Antidepressants
(Tricyclic antidepressants(TCAs))
Antihistamines
Antipsychotics
Anticonvulsants
Anticholinergics
Others
Stub icon

Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Mosapramine&oldid=1181281695"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp